Pargluva (muraglitazar) tablets
NDA 21-865
Advisory Committee Questions
September 9, 2005

1. **Efficacy:**
    a. Do the efficacy findings with Pargluva 2.5 and 5 mg daily support use for the proposed indications in the treatment of type 2 diabetes as:
        i. Monotherapy
        ii. Combination therapy in patients not adequately controlled on metformin or sulfonylurea alone
    b. Is there adequate evidence that Pargluva 1.5 mg daily is effective for the proposed indications?
2. **Safety:**
    a. Do the results of the preclinical studies with muraglitazar and clinical trials with Pargluva 2.5 and 5 mg permit adequate understanding of the risks associated with use, with specific regard to the following issues?
        i. Fluid/electrolyte metabolism
        ii. Cardiac effects
        iii. Hepatic effects
        iv. Muscle effects
3. **Comments/discussion**:
    a. Are there patients for whom treatment with Pargluva 2.5 and 5 mg daily poses particular safety concerns?
    b. Are there patients for whom a lower dose (starting and/or maximum) of Pargluva should be considered?
    c. Comment on concerns about adverse effects (e.g., cardiovascular) of Pargluva beyond those expected based on its mechanism(s) of action.
    d. Comment on the discussions regarding the rodent carcinogenicity of Pargluva and questions of potential human risk.
    e. Other issues

4. **Should Pargluva be approved for the proposed indications?**
    a. Monotherapy
    b. Combination therapy in patients not adequately controlled on metformin or sulfonylurea alone
        i. If yes, comment (for each indication) on doses and special populations.
        ii. If no, what additional information is needed (for each indication)?